Axsome Therapeutics AXSM PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's PP&E (net)?
- Axsome Therapeutics (AXSM) reported PP&E (net) of $567K in Q1 2026.
- How has Axsome Therapeutics's PP&E (net) changed year-over-year?
- Axsome Therapeutics's PP&E (net) decreased by 26.6% year-over-year, from $773K to $567K.
- What is the long-term trend for Axsome Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), Axsome Therapeutics's PP&E (net) has grown at a 60.6% compound annual growth rate (CAGR), from $52.65K to $562K.
- What does PP&E (net) mean?
- The value of the company's physical assets like buildings and equipment, minus depreciation.
- How do you interpret PP&E (net)?
- An increase reflects capital investment in infrastructure, while a decrease may indicate depreciation outpacing new investment.
- How does PP&E (net) compare across companies?
- Biopharma companies often have lower physical asset intensity compared to manufacturing firms, unless they own significant lab facilities.